Suppr超能文献

非酒精性脂肪性肝病中的潜在表观遗传机制。

Potential epigenetic mechanism in non-alcoholic Fatty liver disease.

作者信息

Sun Chao, Fan Jian-Gao, Qiao Liang

机构信息

Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China.

Storr Liver Centre, Westmead Millennium Institute for Medical Research, University of Sydney, the Westmead Clinical School, Westmead Hospital, Westmead, NSW 2145, Australia.

出版信息

Int J Mol Sci. 2015 Mar 5;16(3):5161-79. doi: 10.3390/ijms16035161.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation in the liver. It ranges from simple steatosis to its more aggressive form, non-alcoholic steatohepatitis (NASH), which may develop into hepatic fibrosis, cirrhosis, or hepatocellular carcinoma (HCC) if it persists for a long time. However, the exact pathogenesis of NAFLD and the related metabolic disorders remain unclear. Epigenetic changes are stable alterations that take place at the transcriptional level without altering the underlying DNA sequence. DNA methylation, histone modifications and microRNA are among the most common forms of epigenetic modification. Epigenetic alterations are involved in the regulation of hepatic lipid metabolism, insulin resistance, mitochondrial damage, oxidative stress response, and the release of inflammatory cytokines, all of which have been implicated in the development and progression of NAFLD. This review summarizes the current advances in the potential epigenetic mechanism of NAFLD. Elucidation of epigenetic factors may facilitate the identification of early diagnositic biomarkers and development of therapeutic strategies for NAFLD.

摘要

非酒精性脂肪性肝病(NAFLD)的特征是肝脏中脂肪过度积累。它的范围从单纯性脂肪变性到更具侵袭性的形式,即非酒精性脂肪性肝炎(NASH),如果长期持续,NASH可能发展为肝纤维化、肝硬化或肝细胞癌(HCC)。然而,NAFLD的确切发病机制以及相关的代谢紊乱仍不清楚。表观遗传变化是在转录水平发生的稳定改变,而不改变潜在的DNA序列。DNA甲基化、组蛋白修饰和微小RNA是最常见的表观遗传修饰形式。表观遗传改变参与肝脏脂质代谢、胰岛素抵抗、线粒体损伤、氧化应激反应以及炎症细胞因子释放的调节,所有这些都与NAFLD的发生和发展有关。本综述总结了NAFLD潜在表观遗传机制的当前进展。阐明表观遗传因素可能有助于识别早期诊断生物标志物并制定NAFLD的治疗策略。

相似文献

1
Potential epigenetic mechanism in non-alcoholic Fatty liver disease.
Int J Mol Sci. 2015 Mar 5;16(3):5161-79. doi: 10.3390/ijms16035161.
2
Epigenetics in non-alcoholic fatty liver disease.
Mol Aspects Med. 2017 Apr;54:78-88. doi: 10.1016/j.mam.2016.11.008. Epub 2016 Nov 23.
4
Dysregulated Epigenetic Modifications in the Pathogenesis of NAFLD-HCC.
Adv Exp Med Biol. 2018;1061:79-93. doi: 10.1007/978-981-10-8684-7_7.
5
MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
World J Gastroenterol. 2014 Nov 7;20(41):15079-86. doi: 10.3748/wjg.v20.i41.15079.
7
Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD).
Curr Pharm Des. 2013;19(15):2737-46. doi: 10.2174/1381612811319150009.
8
Genetic and epigenetic mechanisms of NASH.
Hepatol Int. 2016 May;10(3):394-406. doi: 10.1007/s12072-015-9689-y. Epub 2015 Dec 18.
10
Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Free Radic Biol Med. 2017 Oct;111:173-185. doi: 10.1016/j.freeradbiomed.2017.01.023. Epub 2017 Jan 18.

引用本文的文献

2
Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis.
Eng Life Sci. 2023 Jun 2;24(5):2300016. doi: 10.1002/elsc.202300016. eCollection 2024 May.
4
Hepatocytic Ballooning in Non-alcoholic Steatohepatitis: Bridging the Knowledge Gap and Charting Future Avenues.
Cureus. 2023 Sep 25;15(9):e45884. doi: 10.7759/cureus.45884. eCollection 2023 Sep.
5
Role of ammonia in NAFLD: An unusual suspect.
JHEP Rep. 2023 Apr 25;5(7):100780. doi: 10.1016/j.jhepr.2023.100780. eCollection 2023 Jul.
6
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
Front Endocrinol (Lausanne). 2023 Jun 8;14:1148934. doi: 10.3389/fendo.2023.1148934. eCollection 2023.
7
GB1a Activates SIRT6 to Regulate Lipid Metabolism in Mouse Primary Hepatocytes.
Int J Mol Sci. 2023 May 31;24(11):9540. doi: 10.3390/ijms24119540.

本文引用的文献

1
MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
World J Gastroenterol. 2014 Nov 7;20(41):15079-86. doi: 10.3748/wjg.v20.i41.15079.
3
Obesity increases histone H3 lysine 9 and 18 acetylation at Tnfa and Ccl2 genes in mouse liver.
Int J Mol Med. 2014 Dec;34(6):1647-54. doi: 10.3892/ijmm.2014.1958. Epub 2014 Oct 3.
4
Mmu-miR-615-3p regulates lipoapoptosis by inhibiting C/EBP homologous protein.
PLoS One. 2014 Oct 14;9(10):e109637. doi: 10.1371/journal.pone.0109637. eCollection 2014.
5
Aberrant miR199a-5p/caveolin1/PPARα axis in hepatic steatosis.
J Mol Endocrinol. 2014 Dec;53(3):393-403. doi: 10.1530/JME-14-0127. Epub 2014 Oct 13.
6
A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators.
J Gastrointestin Liver Dis. 2014 Sep;23(3):311-9. doi: 10.15403/jgld.2014.1121.233.yck.
7
Circulating microRNAs in patients with non-alcoholic fatty liver disease.
World J Hepatol. 2014 Aug 27;6(8):613-20. doi: 10.4254/wjh.v6.i8.613.
9
A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.
PLoS One. 2014 Aug 20;9(8):e105192. doi: 10.1371/journal.pone.0105192. eCollection 2014.
10
Molecular pathways in non-alcoholic fatty liver disease.
Clin Exp Gastroenterol. 2014 Jul 5;7:221-39. doi: 10.2147/CEG.S62831. eCollection 2014.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验